|Articles|December 7, 2022

mdgroup and Q2 Solutions to Join DTRA Podcast for Discussion on Barriers Between Vendors and Service Providers

As part of the Decentralized Trials and Research Alliance's (DTRA) TGIF-DCT podcast series, mdgroup will join forces with Q2 Solutions to explain how tearing down barriers between the various vendors and service providers involved in such studies is a simple yet effective starting point.

Hosted by DTRA founder Craig Lipset, mdgroup's Director of Decentralized Clinical Solutions, Tom Brazier, will present with Q2 Solutions' Decentralized Trial Solutions Director, John Corcoran, and Manager, Stephanie Larimer.

This event will take place on Dec. 9, 12-1pm, EST. This podcast discussion forms part of a series of Clubhouse events, organized by the DTRA, of which mdgroup is a founding member, aimed at providing all stakeholders with an informal space to share DCT experiences and best practice.

Related to this article

September 30th, 2026

Where AI Leads in Trial Design—and Where Humans Still Need To

In this video interview, Claire Riches, VP of clinical solutions at Citeline, makes the case for AI as a sophisticated strategic advisor in trial design while arguing that humans must remain in the lead—especially when factors the model can't fully account for are at stake.

September 30th, 2026

ACT Brief: Enrollment Feasibility Pressure-Testing, RWE Infrastructure Gaps, and Peptide Rulemaking Standstill

In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.

© FlowStudio - © FlowStudio - stock.adobe.com

September 29th, 2026

Real-World Evidence Is Moving Upstream: Is the Data Infrastructure Ready?

RWE is finding a role earlier in drug development than ever before, but the data quality, integration, and organizational alignment required to make it regulatory-grade are still catching up to the ambition.

September 29th, 2026

The Data Inputs That Matter Most When Pressure-Testing a Protocol's Feasibility

In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains why combining analog trial performance data with real-world patient data and site-level recruitment history gives sponsors a far more honest picture of whether their enrollment assumptions are actually achievable.

September 29th, 2026

ACT Brief: Trial Simulations and Protocol Risk, RBQM Financial Value Quantified, and Three Drug Approvals

In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease.

September 28th, 2026

Quantifying the Financial Value of RBQM: Q&A with Sylviane de Viron, CluePoints, and Abigail Dirks, Tufts CSDD

In this Q&A, Sylviane de Viron of CluePoints and Abigail Dirks, MS, of Tufts CSDD discuss the findings of a collaborative study quantifying the financial value of RBQM, why time savings emerged as the largest driver, and what sponsors struggling to justify adoption now have that they didn't before.

September 28th, 2026

The Design Flaws Trial Simulations Surface That Traditional Planning Misses

In this video interview, Claire Riches, VP of clinical solutions at Citeline, walks through the categories of hidden protocol risk that AI-driven simulations can identify—from overly restrictive eligibility criteria to patient dropout patterns and structural trial assumptions.

September 28th, 2026

ACT Brief: AI Expands Endpoint Options, CRO Oversight Documentation, and Kidney Cancer Approval

In today's ACT Brief, we examine how AI is surfacing endpoint options beyond traditional design thinking, why sponsor oversight of outsourced work often fails on inspection despite being robust in practice, and a new combination drug for advanced kidney cancer.

mdgroup and Q2 Solutions to Join DTRA Podcast for Discussion on Barriers Between Vendors and Service Providers

Related to this article

Trending on Applied Clinical Trials Online

Real-World Evidence Is Moving Upstream: Is the Data Infrastructure Ready?

Sponsor Oversight in an Outsourced Trial: What Good Looks Like and How to Evidence It

The Data Inputs That Matter Most When Pressure-Testing a Protocol's Feasibility

ACT Brief: AI Expands Endpoint Options, CRO Oversight Documentation, and Kidney Cancer Approval

ACT Brief: Trial Simulations and Protocol Risk, RBQM Financial Value Quantified, and Three Drug Approvals